In short
This article discusses a clinical trial investigating the use of a medication containing opium, standardized powdered, along with colchicine, for patients with moderate chronic kidney disease. The study aims to evaluate the effectiveness of this treatment in preventing cardiovascular events and slowing the progression of kidney disease. We'll explore the trial's objectives, eligibility criteria, and potential outcomes for patients with this condition.
At a glance
- Study Name
- COLCHIREN Study
- Main Medication
- Colchicine with Opium, Standardized Powdered
- Dosage
- 0.5 mg/day
- Target Condition
- Moderate Chronic Kidney Disease
- Primary Goal
- Prevent cardiovascular events
- Secondary Goals
- Slow kidney disease progression, evaluate effects on inflammation and fibrosis markers
- Participant Age Range
- 18-99 years
- Treatment Duration
- Up to 36 months
- Key Exclusions
- Recent hospitalizations, active cancer, uncontrolled inflammatory diseases, pregnancy
What is Opium, Standardized Powdered?
Opium, Standardized Powdered is a medicinal substance derived from the opium poppy plant. It is standardized, which means it has a consistent and controlled amount of active ingredients. In the context of this study, it is being used in combination with another medication called colchicine.
Medical Use in Chronic Kidney Disease
The study is investigating the use of opium, standardized powdered, along with colchicine, in patients with moderate chronic kidney disease. Chronic kidney disease is a condition where the kidneys gradually lose their function over time.
The main goal of this research is to see if this combination can help prevent: Cardiovascular events: These are problems related to the heart and blood vessels, such as heart attacks or strokes. Renal progression: This refers to the worsening of kidney disease over time.
Study Details
The study, known as the COLCHIREN study, is looking at the effectiveness of a low dose (0.5 mg per day) of colchicine combined with opium, standardized powdered. It aims to prevent several types of cardiovascular events in patients with moderate chronic kidney disease, including: Cardiovascular death Acute coronary syndrome (a term for conditions where blood flow to the heart is suddenly reduced) Angina requiring hospitalization (chest pain due to reduced blood flow to the heart) Coronary revascularization (procedures to restore blood flow to the heart) Transient ischemic attack or non-cardioembolic ischemic stroke (types of "mini-strokes") Peripheral vasculopathy (problems with blood vessels outside the heart and brain)
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key inclusion criteria are: Age between 18 and 99 years Moderate chronic kidney disease (with specific measures of kidney function) History of a previous cardiovascular event
There are also several exclusion criteria, which include: Allergy or intolerance to colchicine Current or recent treatment with colchicine Recent hospital admission Active cancer Uncontrolled chronic inflammatory diseases Certain infections or liver conditions Pregnancy or breastfeeding
Potential Benefits
The researchers hope that this treatment might: Reduce the risk of future cardiovascular events in patients with moderate chronic kidney disease Slow down the progression of kidney disease Improve markers of inflammation and fibrosis (scarring) in the body
Safety Considerations
As with any medical treatment, safety is a crucial concern. The study will carefully monitor for any side effects or adverse events. Some specific safety considerations include: Avoiding use in patients with certain blood disorders (like low platelet count or anemia) Caution in patients taking certain other medications that might interact with the study drug Close monitoring of kidney function throughout the study
It's important to note that this is a research study, and the benefits and risks of this treatment are still being investigated. Patients should always consult with their healthcare provider before considering participation in any clinical trial.